| Drug General Information |
| Drug ID |
D06NTB
|
| Former ID |
DNC004168
|
| Drug Name |
3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C15H20N2
|
| Canonical SMILES |
CC1CCN(CC1)CC2=CNC3=CC=CC=C32
|
| InChI |
1S/C15H20N2/c1-12-6-8-17(9-7-12)11-13-10-16-15-5-3-2-4-14(13)15/h2-5,10,12,16H,6-9,11H2,1H3
|
| InChIKey |
DGCGMYNLCDVYMB-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
D(4) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
| D(3) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Nicotine Activity on Dopaminergic NeuronsWP58:Monoamine GPCRs
|
|
GPCRs, Other
|
| References |
| REF 1 | J Med Chem. 1996 May 10;39(10):1941-2.3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. |
|---|
